Endometrial Genomic Profile in Endometrial Priming

Instituto Valenciano de Infertilidad, IVI VALENCIA

Status: Completed

Conditions: Genomic Human Endometrial Expression Profile

Treatments: Procedure: endometrial biopsy

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01778452

VLC18012013

Details and patient eligibility

About

The aim of this study is to analyse genomics profile expression in endometrium under different endometrial priming for recipients.

Full description

We analyze the genomic profile of egg donors in different endometrial priming protocols, compared with natural cycle, including the conventional single long acting GnRH agonist injection in the mid luteal phase of the previous cycle of the endometrial priming and the single daily antagonist injection (Cetrorelix 0.25 mg) administered in the early follicular phase followed by endometrial priming. Endometrial biopsy will be taken in luteinizing hormone

• 7 or with P4 +5 in cases with endometrial priming with oestrogens therapy.

Enrollment: 6 patients

Sex: Female

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 6 egg healthy volunteer egg donors.
• Volunteers.
• 18-35 years old
• Healthy.
• BMI <28.

Exclusion criteria

• • BMI > 28
• Smokers-

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

6 participants in 3 patient groups

Natural cycle

Active Comparator group

Description:

Natural cycle endometrial biopsy, lh+7

Treatment:

Procedure: endometrial biopsy

Antagonist cycle + endometrial priming.

Experimental group

Description:

Antagonist cycle + endometrial priming for egg donation program. endometrial biopsy, p4+5

Treatment:

Procedure: endometrial biopsy

Agonist cycle + endometrial priming.

Experimental group

Description:

Agonist cycle + endometrial priming for egg donation program endometrial biopsy, p4+5

Treatment:

Procedure: endometrial biopsy